Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening ...

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience.

Dexcom is transforming its Stelo CGM into a whole-family wellness device, securing FDA clearance for pediatric use and debuting new AI tools.

AI can help read CGM data for glucose forecasts, but broader health profiling still faces validation, privacy, and governance ...

Signos Inc. announced today results from a real-world study demonstrating that adults with obesity without diabetes who ...

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...

Children may experience shorter sensor wear times due to physical and behavioral differences. The Food and Drug Administration (FDA) has cleared Dexcom’s Stelo Glucose Biosensor System for children ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom received FDA clearance for its first over-the-counter continuous glucose monitor, called Stelo. The device is intended for ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...